German Tamoxifen Shortage Shows Consequences Of Cost Containment
Medicines For Europe Urges Change To ‘Unsustainable’ Procurement Policies
Supply issues around breast cancer treatment tamoxifen in Germany demonstrate the damaging effects of European cost-containment measures, Medicines for Europe has warned, citing an “urgent need to revise unsustainable pricing and tendering policies.”
You may also be interested in...
Further analysis is under way, but first impressions by EU R&D industry group EFPIA of policy proposals for tackling drug shortages are not good.
A European Commission study into the root causes of medicines shortages has identified a range of potential solutions, with the Commission identifying older, off-patent and generic drugs as the most at-risk.
Medicines for Europe has urged the European Commission to enshrine security of supply considerations for essential medicines into legislature. Without these, additional cost containment measures for off-patent medicines under consideration by member states may ultimately threaten access by making production unsustainable for manufacturers.